Helius Medical Technologies, Inc. to Present at Four Upcoming Investor Conferences in January
Helius Medical Technologies (Nasdaq:HSDT) has announced participation in several virtual investor conferences during January 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Helius Medical Technologies (Nasdaq:HSDT) has announced participation in several virtual investor conferences during January 2021. Key events include:
- The Demy-Colton Digital Medicine and Medtech Showcase from January 11-15, with on-demand access starting January 6th.
- The H.C. Wainwright BioConnect Conference from January 11-14, with presentations available on January 11th.
- The Sidoti Winter 2021 Conference on January 13-14, where management will present on January 13th.
- The ICR Conference from January 11-14, with management presenting on January 14th.
Details
News Market Reaction – HSDT
The recorded move for HSDT in the trading session of this news was -14.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTOWN, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences in January:
The Demy-Colton Digital Medicine and Medtech Showcase 2021, which is being held virtually from January 11th-15th.
- The Company’s presentation will be available on-demand beginning on Wednesday, January 6th at 8:30 a.m. Eastern Time.
The H.C. Wainwright BioConnect Conference, which is being held virtually from January 11th-14th.
- The Company’s presentation will be available on-demand beginning on Monday, January 11th at 6:00 a.m. Eastern Time.
The Sidoti Winter 2021 Investor Conference, which is being held virtually from January 13th-14th.
- Management will present on Wednesday, January 13th at 1:45 p.m. Eastern Time.
The ICR Conference 2021, which is being held virtually from January 11th-14th.
- Management will present on Thursday, January 14th at 10:45 a.m. Eastern Time.
Webcasts of the presentations will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. Archives of the webcasts will be available for replay following the conference.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The device is currently under review for clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS™ is currently not commercially available in the United States, the European Union or Australia.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
investorrelations@heliusmedical.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.